TCI Wealth Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

TCI Wealth Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-508	Closed	-$9K	–	2638
2021 Q3	$9K	Buy	508 +208	+69%	+$2.43K	﹤0.01%	1214
2021 Q2	$3K	Sell	300 -400	-57%	-$3.77K	﹤0.01%	1924
2021 Q1	$8K	Hold	700	–	–	﹤0.01%	1020
2020 Q4	$10K	Buy	700 +200	+40%	+$2.88K	﹤0.01%	664
2020 Q3	$7K	Buy	500 +100	+25%	+$997	﹤0.01%	695
2020 Q2	$3K	Sell	400 -200	-33%	-$1.24K	﹤0.01%	1002
2020 Q1	$2K	Buy	+600	New	+$2.27K	﹤0.01%	1150

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

TCI Wealth Advisors's TRIL Position: Q4 2021 in Review

TCI Wealth Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 508 shares — an estimated $9K sold.

TCI Wealth Advisors first reported a position in TRIL in Q1 2020 and held it in 7 quarters. The position peaked at $10K in Q4 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

TCI Wealth Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
TCI Wealth Advisors sold 508 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $9K.
TCI Wealth Advisors first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 7 quarters.
TCI Wealth Advisors's Trillium Therapeutics Inc. position peaked at $10K in Q4 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on TCI Wealth Advisors's 13F filing for Q4 2021, filed 24 Jan 2022.